Fig. 4

Dose-dependent inhibition of tumour growth by [¹⁷⁷Lu]Lu-DOTA-Miltuximab®. DU-145-RFP-Luc cells (5 × 10⁶ in Matrigel) were injected subcutaneously into the right flank of BALB/c/nude mice. On day 25, the mice received either DOTA-Miltuximab® (n = 8), 3 MBq [¹⁷⁷Lu]Lu-DOTA-Miltuximab® (n = 9) or 10 MBq [¹⁷⁷Lu]Lu-DOTA-Miltuximab® (n = 9) intravenously. Mice were weighed and tumour volumes measured via callipers twice weekly. a Mean mouse weight over time. b Mean weekly mouse tumour volume. *p < 0.05; **p < 0.01; ***p < 0.001 by one-way ANOVA followed by Dunnett’s multiple comparisons test. c Tumour Control Index (TCI), stability and regression scores. Statistical analysis was one-way ANOVA followed by Tukey’s multiple comparisons test. d Kaplan-Meier survival curve. Comparison of survival curves was performed using a log-rank (Mantel-Cox) test